LGX818 for Patients With BRAFV600 Mutated Tumors

Inclusion Criteria

- Patient has a confirmed diagnosis of a select solid tumor (except with a primary
diagnosis of melanoma and colorectal cancer (CRC)) or hematologic malignancies and is
in need of treatment because of progression or relapse.

- Patient's tumor has been evaluated and pre-identified as having a tumor with a
BRAFV600 mutation at a CLIA certified laboratory.

- Patient must have received at least one prior treatment for recurrent, metastatic and
/or locally advanced disease and for whom no standard therapy options are anticipated
to result in a durable remission.

- Patient must have progressive and measurable disease per RECIST 1.1. or other
appropriate hematological response criteria.

- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

Exclusion Criteria:

- Patient has received prior treatment with LGX818.

- Patients with Central Nerve System (CNS) metastasis or leptomeningeal carcinomatosis.

- Patient has received chemotherapy or other anticancer therapy ≤ 4 weeks (6 weeks for
nitrosourea, antibodies or mitomycin-C) prior to starting study drug.

- Patients with acute or chronic pancreatitis.

- Patients with impaired cardiac function or clinically significant cardiac diseases.

- Patients with another primary malignancy within 3 years prior to starting study
treatment, with the exception of adequately treated basal cell carcinoma, squamous
cell carcinoma or other non-melanomatous skin cancer, or in-situ carcinoma of the
uterine cervix.